NeuroMab™ Anti-BACE1 Antibody(NRP-0422-P1004)

Product Overview

Description

The antibody specifically binds to the human BACE1 protein, and can be useded for inhibiting amyloid-β formation and/or aggregation, inhibiting amyloid plaque formation, and treating neurodegenerative diseases.

Species Reactivity

Human

Clonality

Monoclonal

Host Species

Mouse

Applications

Inhib; WB; In Vitro; In Vivo

Application Notes

BACE1

Relevant Diseases

Alzheimer's Disease

Product Properties

Preservatives

BSA Free

Concentration

1mg/mL

Endotoxin Level

Regular Endotoxin < 5 EU/mg
Low Endotoxin < 1 EU/mg

Shipping

Gel Packs

Storage

Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Research Use Only

For research use only

Target

BACE1

Official Name

BACE1

Full Name

Beta-Secretase 1

Alternative Names

Beta-Secretase 1; Membrane-Associated Aspartic Protease 2; Beta-Site APP Cleaving Enzyme 1; Beta-Site APP-Cleaving Enzyme; Aspartyl Protease 2; EC 3.4.23.46; Memapsin-2; Asp 2; BACE; ASP2;

Gene ID

23621 (Human); 23821 (Mouse); 29392 (Rat)

Uniprot ID

P56817 (Human); P56818 (Mouse); P56819 (Rat)

Product Pictures

FuncS

Figure 2 shows the induction of a mouse TREM2-dependent luciferase reporter gene in a cell-based assay.

Cells were either untreated (NT) or treated with soluble full-length anti-TREM2 antibodies 1H7, 2F6, 2H8, 3A7, 3B10, 7E5, 7F8, 8F8, and 11H5. Antibody mlgG1 is an isotype negative control. Cells treated with PMA/ionomycin represent a positive control. Results are represented as folded backgrounds (indicated by dashed lines).

FuncS

Figure 4 shows the concentration of CCL4 (pg/ml) in the peritoneal cavity after injection of control (CTR) or TREM2 antibodies 7E5 and 8F8 in combination with LPS.

FuncS

Figure 3 shows the induction of a mouse TREM2-dependent luciferase reporter gene in a cell-based assay. Cells were either untreated (NT) or treated with soluble full-length anti-TREM2 antibodies 1H7, 2F6, 2H8, 3A7, 3B10, 7E5, 7F8, 8F8, and 11H5.

FuncS

Figure 1 shows wild-type (WT) bone marrow-derived mouse macrophages treated with 100 nM soluble full-length anti-TREM2 antibodies 1H7, 2F6, 2H8, 3A7, 7E5, 7F8, and 8F8 or a commercial antibody (R&D Cat #F7E57291).

Publications